


Platelet Aggregation Inhibitors

Novel antagonists of the P2Y₁₂-receptor with antithrombotic effect

Invention

Purinergic receptors have been in the focus of drug discovery for many years. Modulation of P2 receptors in platelets is of paramount importance in regulating platelet function, and, as a consequence, in controlling thrombotic diseases, which are the most common cause of morbidity and mortality in the Western world.



Example of general formular of disclosed compounds - further specified in the patent applicatio

The P2Y₁₂-receptor on blood platelets is the target of known antithrombotic drugs (e.g. clopidogrel). The receptor is therefore validated for this therapeutic use. Furthermore, the P2Y₁₂-receptor is expressed in certain parts of the brain, which opens new routes for the treatment of neuroinflammatory and neurodegenerative diseases.

This invention provides novel antagonists of the P2Y₁₂-receptor. The disclosed novel compounds show reversible and selective binding to the P2Y₁₂-receptor. The molecules do not require bioactivation. Further the

patent application discloses synthesis of the compounds with optimised product yield

Commercial Opportunities

We offer a patent license as well as a research collaboration with licensing option to innovative companies.

Current Status

Patent applications for the invention have been filed in Europe and North America.

An invention of Rheinische Friedrich-Wilhelms-Universität Bonn (UniBonn).

Competitive Advantages

- **Innovative group of compounds for a validated target;**
- **No bioactivation for faster onset of action;**
- **Reversible binding to the receptor;**
- **Small molecules for in-expensive production process.**

Contact:
Ref. No.: 1526
Dr. Andreas Wagener

PROvendis GmbH
Schlossstrasse 11-15
D-45468 Muelheim an der Ruhr,
Germany
Phone: +49 (0)208 94 105 38
Fax: +49 (0)208 94 105 50
Email: aw@provendis.info
Web: www.provendis.info